Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study

Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study

Abstract This study (NCT04728035) aimed to explore the safety and efficacy of liposomal irinotecan (HE072) in patients with metastatic triple-negative breast cancer (mTNBC). This study consisted of two parts. In part 1, the 3 + 3 design was used to investigate three dose levels of HE072 (50, 70 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Fan, Qingyuan Zhang, Min Yan, Xiujuan Qu, Yongmei Yin, Tao Sun, Jin Yang, Ying Wang, Xu Wang, Zhaofeng Niu, Xinshuai Wang, Sanyuan Sun, Weihong Zhao, Yanping Liu, Miao Niu, Xuemin Zhao, Binghe Xu
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-55090-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-55090-4

Similar Items